COGT
Cogent Biosciences Inc
32.30$
+2.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -20.3% | -35.0% | +75.0% | -42.5% | +407.7% | -7.5% | +29.6% | +4.2% | +4.6% | +185.9% | |
| – | -23.5% | -39.2% | +91.1% | -49.9% | +503.4% | -9.1% | +19.0% | +2.2% | +9.5% | +207.1% | |
| – | -54.3% | -31.6% | +96.9% | -32.8% | +547.2% | -9.3% | -36.3% | -61.9% | +84.4% | +217.8% | |
| – | -24.3% | -40.2% | +91.9% | -52.4% | +547.2% | -9.3% | +18.0% | +2.5% | +8.0% | +213.8% | |
| – | +215.6% | -10.6% | +101.0% | +19.9% | -100.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -33.6% | -64.1% | +356.2% | – | – | – | |
| – | -8.3% | -10.2% | +23.5% | -31.3% | -8.0% | +10.2% | +151.7% | +23.4% | +28.7% | +320.7% | |
| – | +19.8% | +28.1% | +122.9% | -46.9% | -1.2% | +30.4% | +57.2% | +42.2% | +46.0% | +14.8% | |
| – | +120,199,900.0% | +130.7% | +37.0% | -57.4% | +26.7% | +13.3% | -38.8% | -2.6% | +12.9% | -1.2% | |
| – | +4.2% | -7.4% | +12.9% | +109.5% | -77.0% | +375.8% | +67.7% | +82.4% | +12.7% | -20.9% | |
| – | – | – | – | – | – | – | – | – | – | – | |
| – | -24.6% | -46.0% | +112.8% | -47.3% | +638.8% | -8.7% | +19.4% | +0.8% | -0.6% | +148.3% | |
| – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | -15.9% | +22.4% | +45.4% | +249.5% | +51.7% | +35.6% | +38.7% | +45.7% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.